Navigation Links
Cetero Research Names 25-Year Industry Veteran James Dixon to Head Quality and Compliance
Date:4/26/2011

CARY, N.C., April 26, 2011 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), today announced the appointment of James "Jay" Dixon to Senior Vice President, Quality and Compliance. Dixon has spent more than 25 years in the pharmaceutical, biotechnology and CRO industries, and will bring his extensive experience to support Cetero's objective of maintaining its market leadership position.

(Photo:  http://photos.prnewswire.com/prnh/20110426/PH89541 )

At Cetero, Dixon will lead the Quality and Compliance team, ensuring that Cetero's unwavering commitment to quality provides its clients with the most dependable and accurate results.

"We are thrilled to have someone of Jay's caliber joining the Cetero team," said CEO Troy W. McCall, Ph.D. "Cetero considers quality and compliance to be the utmost priority. Jay's qualifications and background will undoubtedly help raise Cetero's benchmark for quality to an unprecedented new level."

Dixon's career has focused on clinical (GCP), preclinical (GLP), manufacturing (GMP) quality, medical operations and analytical chemistry. Dixon most recently led the quality and compliance efforts for MedImmune, LLC, as Vice President of GxP Quality Compliance. Prior to that, he was at Covance Central Laboratory Services as Vice President of Global Quality Assurance and Business Process Improvement – Six Sigma.

"Quality, safety and consistency are more important than ever in our industry," Dixon said. "I am committed to building upon Cetero's reputation as the leader in early-stage clinical research and to further improving on our record of high-quality performance and reliability."

Prior to his work at Covance, Dixon also held quality-focused leadership positions at Abbott Laboratories, Inc., Triangle Pharmaceuticals (now Gilead Sciences), PAREXEL International Corporation, ClinTrials Research, Inc., Glaxo, Inc. and Glaxo Wellcome, Inc. Dixon holds a bachelor's degree in biology from Campbell University in North Carolina. He is a member of the Board of Directors of Frederick Memorial Healthcare System in Frederick, Maryland, the Drug Information Association (DIA) and the Society of Quality Assurance (SQA).

About Cetero Research

Cetero Research, the leading early-phase contract research organization (CRO), has conducted more than 20,000 clinical pharmacology studies, more than any other CRO. With facilities across North America, Cetero offers flexible, high-quality clinical development services in a range of therapeutic areas, including asthma and allergy, dermatology and diabetes, as well as bioanalytical services to support clinical, preclinical drug and biomarker analysis for small and large molecules. It uses innovative approaches, such as the Accelerated Proof-of-Concept study design to provide key decision-making data earlier in the development process. A pioneer in the pharmaceutical and biotechnology industries, Cetero prioritizes ensuring the safety of its patient and normal healthy study participants, reporting high-quality, reliable data and providing on-time results. For more information, visit www.cetero.com or call 877.7CETERO


'/>"/>
SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Leads Industry in Human Allergy Models
2. Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
3. Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
4. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
5. Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
10. Video: New Research Discovers Independent Brain Networks Control Human Walking
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
(Date:6/8/2017)... MCKINNEY, Texas , June 8, 2017 ... Company"), a leading developer and manufacturer of ... industry, announced today that Cressey & Company ... investment firm, has completed a growth-focused investment ... acquired a majority ownership position from selling ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... 2017 , ... Yesterday, U.S. Senate Republicans revealed details of ... replace the Affordable Care Act (ACA). Like the bill narrowly passed by the ... public health insurance program for low-income children, pregnant women, parents of dependent children, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. Rubinstein ... recently begun offering three new minimally invasive procedures to patients who want a ... downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich ...
(Date:6/23/2017)... ... 23, 2017 , ... Goodcents Deli Fresh Subs today announced the opening of ... SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is owned and ... three other locations in the Topeka and Bonner Springs, Kan. area. , “Goodcents ...
(Date:6/23/2017)... Atlanta, Georgia (PRWEB) , ... June 23, 2017 ... ... Triple Negative Breast Cancer Conference from Sept. 18 to 20. , The two-day ... cancer (TNBC) subtype with the goal of improving patients’ lives and eliminating racial ...
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased to announce ... for CDA members. As part of the amalgam separator endorsement, all CDA members may ... than $400 off the retail value. This partnership between PureLife and CDA is especially ...
Breaking Medicine News(10 mins):